Oncology CRO | Avance Clinical at ESMO Congress 2026

Yes. Avance Clinical’s Oncology Center of Excellence leadership team will be attending ESMO Congress 2026, 23–27 October 2026, at IFEMA Madrid in Madrid, Spain, available for dedicated meetings by appointment.

Avance Clinical’s Oncology Center of Excellence leadership team, including Executive Medical Director, George Peoples is attending ESMO Congress 2026.

It is Avance Clinical’s dedicated capability for oncology and immuno-oncology drug development, combining adaptive and Bayesian early-phase trial design, deep scientific leadership, and a global footprint from first-in-human through late-phase development.

Avance Clinical pairs Australia’s early-phase advantages (including no TGA pre-approval for most oncology programs, 5-6 week study start-up, and data accepted by the FDA and EMA) with a GlobalReady model spanning Australia, Asia-Pacific, China, North America, and Europe, so European sponsors get one CRO across every region their program will touch.

Most oncology first-in-human and dose-escalation studies can start under Australia’s CTN pathway without TGA pre-approval, saving up to a year in regulatory processing time compared with a full IND submission. Gene therapies and certain complex cell therapies go through a separate TGA review pathway instead. Study start-up with Avance Clinical runs 5-6 weeks from final protocol to approval, and eligible biotechs can access R&D rebates of up to 43.5% on eligible spend.

Avance Clinical has supported more than 260 oncology trials in the last five years, spanning solid tumors (including NSCLC, melanoma, ovarian cancer, and glioblastoma), hematological malignancies, rare oncology indications, and novel-modality programs.

Sponsors can book a dedicated meeting with Avance Clinical’s Oncology Center of Excellence leadership team in advance via the Avance Clinical website.